Clinical reviewDreaming under antidepressants: A systematic review on evidence in depressive patients and healthy volunteers
Introduction
Antidepressants (ADs), besides antihyperlipidemic agents and analgesics, are the most prescribed drugs in the U.S.1 In 2006, the prevalence of a lifetime experience of a depressive disorder was 15.7% among U.S. residents aged 18 or older; a 35% increase is expected by 2050.2 The estimated economic burden of depression in the U.S. rose from $77.4 billion in 1990 (inflation-adjusted dollars) to $83.1 billion in 2000.3 Although ADs have a strong impact on sleep and also on dreaming,4, 5 the magnitude and characteristics of AD influence on dreaming have found little attention in efforts to map AD effects.
The importance of ADs is highlighted not only by their therapeutic use for depressive disorders but also by their use in a variety of diseases with impact on the mental state such as insomnia, anxiety disorder, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder, and chronic pain.6, 7 Furthermore, there is an increasing field for cognitive enhancing and lifestyle use of ADs.8
One of the primary features of depression is disordered sleep. At the subjective level, depression is associated with insomnia,9 difficulty in falling asleep, frequent nocturnal awakenings, nonrestorative sleep, and early morning awakening. Reduction of rapid eye movement (REM) sleep latency is one of the most robust and specific features of sleep in depressed patients and considered a trait marker of depression.10, 11, 12 Numerous other polysomnographic features of altered sleep in depression have been documented, such as increases in REM density, duration of first REM sleep period, time of REM sleep, sleep latency, as well as waking time, and decreases in total sleep time, slow wave sleep, sleep continuity, and sleep efficiency.4, 9, 13
Successful improvement of depressive mood by treatment with ADs may be accompanied by different effects on sleep. Triciyclic ADs tend to improve sleep quality and total sleep time,14 while most selective serotonin reuptake inhibitors (SSRIs) tend to cause insomnia and to reduce total sleep time.15 The effects of most ADs on REM sleep are strong and relatively consistent: a prolongation of REM sleep latency and a reduction of REM sleep time.4, 16, 17, 18, 19 In patients with depression and reduced REM latencies, amitryptiline induced REM sleep suppression during the first two treatment nights, correlated with good clinical response.14, 20 However, this finding was not consistently confirmed.21 Monoamine oxidase inhibitors may virtually eliminate REM sleep,19, 22, 23 a phenomenon that neither necessarily produces a positive clinical response in patients nor causes obvious harm.19
The following features have been described in dreams of depressive patients: reduced dream recall frequency (DRF),*24, 25 reduced length of reports,26, 27 dream contents ranging from “mundane”,26, 28 “trivial”,26 to increased “masochistic”,29, 30, 31, 32 vivid, disturbing, and sometimes emerging as nightmares.9 In psychotherapeutic settings, dream content correlated with therapy outcome. In depressed female divorcees, an increase in masochism across the night was a poor prognostic sign.31 Depressed divorcees who incorporated the loss in their dreams and had stronger affects in dreams were finally better adjusted to their new life.33 High masochism scores in dreams of depressed women were related to a decreased likelihood of clinical improvement.32 Even after full clinical remission for at least six months and no chronic use of psychotropic drugs for at least two months, formerly depressive patients still showed significant negative features in REM dreams.30 This included: increased masochism, increased hostility in the environment, more inanimate objects exerting physical effort, more dreaming of the past, and shorter narratives.30
Section snippets
Rationale
Negatively altered dreams are a concomitant phenomenon of depressive disorders. The study of dream in a disease context has a long tradition, primarily in psychoanalysis. After the discovery of REM sleep34 with its undeniable link to dreams and after development of AD drugs, clear-cut data emerged that depression is accompanied by reduced REM sleep latency and increased REM sleep density35 and that most ADs have a strong REM sleep reducing effect. REM sleep reduction by ADs may have a
Methods
A systematic review40 was performed, screening the data sources Ovid MEDLINE, Cochrane Library, PsycNET/PsycINFO, Virtual Health Library, and clinical trial register websites (e.g., clinicaltrials.gov, apps.who.int/trialsearch) for articles in English, German, Spanish, Portuguese, French, and Italian. Used search terms were “dream*(-s, -ing)”, “nightmare*(s)”, and “antidepress*(-ant, -ants, -ive)”, the observation period was 1950 to August 2010. To identify further studies, reference lists of
Results
Using the search terms “dream*(-s, -ing)”, “nightmare*(s)”, and “antidepress*(-ant, -ants, -ive)”, Ovid MEDLINE retrieved 97 abstracts; three of them double citations, 10 reviews, and 35 not fulfilling abstract screening criteria (investigating PTSD 9, medications other than ADs 6, children 5, narcolepsy 4, Parkinson's disease 2, schizophrenia 2, other reasons 7). The remaining 49 papers were full-text screened and 28 full papers were considered suitable for structured data extraction according
Discussion
The reviewed studies document a clear effect of ADs on dream recall and dream content. The major finding is a decrease of DRF under ADs, a rather consistent effect in tricyclic ADs*39, 44, 52 and phenelzine,19, 53 less consistently documented also for SSRIs/SNRIs.*24, *57 ADs reduced DRF both in depressed patients14, 19, 33, 45 and in normal volunteers.35, 44, 49 Administration of SSRIs/SNRIs may increase frequency of nightmares.61 Withdrawal of tricyclic ADs,52, 64 phenelzine,53 and
Conclusions
Considering treatment process, the various classes of ADs have a different potential to reduce DRF, which is accompanied by a spectrum of impact on dream content. Especially in psychotherapy and psychoanalytic dream work in depressed patients, a more personalized approach toward AD pharmacotherapy120 may be implemented, according to patients' needs. Pharmacological effects of ADs, as well as of other psychotropic drugs, on dreaming are theoretically and clinically relevant. They should be
Acknowledgments
The authors declare no conflict of interests. The study received no funding.
References∗ (120)
Health, United States, 2010: with special feature on death and dying
(2011)- et al.
Population projection of US adults with lifetime experience of depressive disorder by age and sex from year 2005 to 2050
Int J Geriatr Psychiatry
(2008) - et al.
The economic burden of depression in the United States: how did it change between 1990 and 2000?
J Clin Psychiatry
(2003) Depression, sleep, and antidepressants
J Clin Psychiatry
(1998)- et al.
Depression, sleep physiology, and antidepressant drugs
Depress Anxiety
(2001) - et al.
Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database
BMJ
(2009) - et al.
Prevalence, duration and indications for prescribing of antidepressants in primary care
Age Ageing
(2006) Pursued by happiness and beaten senseless. Prozac and the American dream
Hastings Cent Rep
(2000)Sleep in psychiatric disorders
Neurol Clin
(1996)- et al.
Successful separation of depressed, normal, and insomniac subjects by EEG sleep data
Arch Gen Psychiatry
(1979)
EEG sleep in outpatients with generalized anxiety: a preliminary comparison with depressed outpatients
Psychiatry Res
Sleep and psychiatric disorders. A meta-analysis
Arch Gen Psychiatry
Sleep and depression
J Clin Psychiatry
The relationship between changes in REM sleep and clinical improvement in depressed patients treated with amitriptyline
Psychopharmacology (Berl)
Effect of pharmacologic treatments on the sleep of depressed patients
Biol Psychiatry
Drug effects on REM sleep and on endogenous depression
Neurosci Biobehav Rev
Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression
Sleep
The link between sleep and depression: the effects of antidepressants on EEG sleep
J Psychosom Res
Sleep and sleep electroencephalogram in depressed patients treated with phenelzine
Arch Gen Psychiatry
EEG sleep changes as predictors in depression
Am J Psychiatry
Sleep EEG and amitryptiline treatment in depressed inpatients
Biol Psychiatry
REM sleep and central monoamine oxidase inhibition
Psychopharmacologia
REM sleep suppression induced by selective monoamine oxidase inhibitors
Psychopharmacology (Berl)
Dream recall and major depression: a preliminary report
Dreaming
Dream recall in depressed patients
Psychother Psychosom Med Psychol
Investigations of morning and laboratory dream recall and content in depressive patients during baseline conditions and under antidepressive treatment with trimipramine
Psychiatr J Univ Ott
Comparison of dream content of depressed vs nondepressed dreamers
Psychol Rep
Dreaming away depression: the role of REM sleep and dreaming in affective disorders
J Affect Disord
Dreams of depressed patients. Characteristic themes in manifest content
Arch Gen Psychiatry
Dreams in patients remitted from reactive depression
J Abnorm Psychol
Dream dimension differences during a life change
Psychiatry Res
The contribution of dream masochism to the sex ratio difference in major depression
Psychiatry Res
Dreams that work: the relation of dream incorporation to adaptation to stressful events
Dreaming
Regularly occurring periods of eye motility, and concomitant phenomena, during sleep
Science
Depression and sleep–the status of current research
Fortschr Neurol Psychiatr
Antidepressants and sleep: a qualitative review of the literature
Drugs
L'esperienza del sogno in pazienti depressi e le modificazioni indotte dal trattamento con farmaci antidepressivi
Rivista di psichiatria
Drugs and dreams
The effect of trimipramine on dream recall and dream emotions in depressive outpatients
Psychiatry Res
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
BMJ
Drug-induced nightmares
Ann Pharmacother
Serotonin and dreaming
Long-term psychotropic drug administration: effects on dream content and dream density
Sleep Res
Drugs and dreams. II. Imipramine and prochlorperazine
Compr Psychiatry
Drugs and dreams 3. The effects of imipramine on the dreams of depressed patients
Am J Psychiatry
Attività onirica dei depressi
Archivio di psicologia, neurologia e psichiatria
The effects of long term administration of psychotropic drugs on human sleep. I. Methodology and the effects of placebo
Psychopharmacologia
The effects of long term administration of psychotropic drugs on human sleep. 3. The effects of amitriptyline
Psychopharmacologia
Depression: dreams and defenses
Am J Psychiatry
Dreaming in the depressed
Can Psychiatr Assoc J
Cited by (57)
REM sleep function: Mythology vs. reality
2023, Revue NeurologiqueNeurobiology of dreams
2023, Encyclopedia of Sleep and Circadian Rhythms: Volume 1-6, Second EditionTherapeutic and adverse drug effects
2023, Encyclopedia of Sleep and Circadian Rhythms: Volume 1-6, Second EditionDream content and depressive symptoms during pregnancy and postpartum
2023, Journal of Affective Disorders ReportsTrauma survivors with disrupted sleep generate less specific and less emotional autobiographical memories
2021, Journal of Affective Disorders ReportsCitation Excerpt :Other general exclusion criteria were: (a) history of alcohol or other substance abuse, (b) age < 25 years or > 40 years, (c) current prescription for sedative or psychoactive medication, (d) experience of trauma > 5 years or < 6 months prior to study enrolment, and (e) history of neurological insult. We set these criteria in place to minimize potential confounds related to altered sleep patterns and/or impaired memory processing as a consequence of factors not examined here (Brower, 2001; Chokroverty and Nobili, 2017; Espiritu, 2008; Foral et al., 2011; Grima et al., 2016; Hasler et al., 2012; Ohayon et al., 2004; Teicher et al., 2016; Tribl et al., 2013). Ultimately, 60 women whom we screened met criteria for participation.
Dreams and nightmares in healthy adults and in patients with sleep and neurological disorders
2020, The Lancet Neurology
- d
Tel.: +49 9419415068.
- e
Tel.: +49 62117031782.
- ∗
The most important references are denoted by an asterisk.